-
Add to Cart The item has been addedAb182851-5mgObexelimab (anti-CD19) is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Obexelimab (anti-CD19) can be used in research of autoimmune.Purity≥95% (SDS-PAGE&:SEC)Endotoxin Level <: 0.01EU/μg. -
Add to Cart The item has been addedAb182851-1mgObexelimab (anti-CD19) is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Obexelimab (anti-CD19) can be used in research of autoimmune.Purity≥95% (SDS-PAGE&:SEC)Endotoxin Level <: 0.01EU/μg. -
Add to Cart The item has been addedAb182851-10mgObexelimab (anti-CD19) is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Obexelimab (anti-CD19) can be used in research of autoimmune.Purity≥95% (SDS-PAGE&:SEC)Endotoxin Level <: 0.01EU/μg. -
Add to Cart The item has been addedAb182851-100μgObexelimab (anti-CD19) is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Obexelimab (anti-CD19) can be used in research of autoimmune.Purity≥95% (SDS-PAGE&:SEC)Endotoxin Level <: 0.01EU/μg. -
Add to Cart The item has been addedAb182827-5mgFrovocimab (anti-PCSK9) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab (anti-PCSK9) inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact -
Add to Cart The item has been addedAb182827-1mgFrovocimab (anti-PCSK9) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab (anti-PCSK9) inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact -
Add to Cart The item has been addedAb182827-10mgFrovocimab (anti-PCSK9) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab (anti-PCSK9) inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact -
Add to Cart The item has been addedAb182827-100μgFrovocimab (anti-PCSK9) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab (anti-PCSK9) inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact -
Add to Cart The item has been addedAb182811-5mgZalifrelimab (anti-CTLA-4) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab (anti-CTLA-4) antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.Purity>:95% -
Add to Cart The item has been addedAb182811-1mgZalifrelimab (anti-CTLA-4) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab (anti-CTLA-4) antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.Purity>:95% -
Add to Cart The item has been addedAb182811-10mgZalifrelimab (anti-CTLA-4) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab (anti-CTLA-4) antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.Purity>:95% -
Add to Cart The item has been addedAb182811-100μgZalifrelimab (anti-CTLA-4) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab (anti-CTLA-4) antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.Purity>:95%
